> Detailanzeige

Nguyen, Van Thien Chi; Nguyen, Trong Hieu; Doan, Nhu Nhat Tan; Pham, Thi Mong Quynh; Nguyen, Giang Thi Huong; Nguyen, Thanh Dat; Tran, Thuy Thi Thu; Vo, Duy Long; Phan, Thanh Hai; Jasmine, Thanh Xuan; Nguyen, Van Chu; Nguyen, Huu Thinh; Nguyen, Trieu Vu; Nguyen, Thi Hue Hanh; Huynh, Le Anh Khoa; Tran, Trung Hieu; Dang, Quang Thong; Doan, Thuy Nguyen; Tran, Anh Minh; Nguyen, Viet Hai; Nguyen, Vu Tuan Anh; Ho, Le Minh Quoc; Tran, Quang Dat; Pham, Thi Thu Thuy; [...]

Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization
  • Beteiligte: Nguyen, Van Thien Chi; Nguyen, Trong Hieu; Doan, Nhu Nhat Tan; Pham, Thi Mong Quynh; Nguyen, Giang Thi Huong; Nguyen, Thanh Dat; Tran, Thuy Thi Thu; Vo, Duy Long; Phan, Thanh Hai; Jasmine, Thanh Xuan; Nguyen, Van Chu; Nguyen, Huu Thinh; Nguyen, Trieu Vu; Nguyen, Thi Hue Hanh; Huynh, Le Anh Khoa; Tran, Trung Hieu; Dang, Quang Thong; Doan, Thuy Nguyen; Tran, Anh Minh; Nguyen, Viet Hai; Nguyen, Vu Tuan Anh; Ho, Le Minh Quoc; Tran, Quang Dat; Pham, Thi Thu Thuy; [...]
  • Erschienen: eLife Sciences Publications, Ltd, 2023
  • Erschienen in: eLife, 12 (2023)
  • Sprache: Englisch
  • DOI: 10.7554/elife.89083.3
  • ISSN: 2050-084X
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: Despite their promise, circulating tumor DNA (ctDNA)-based assays for multi-cancer early detection face challenges in test performance, due mostly to the limited abundance of ctDNA and its inherent variability. To address these challenges, published assays to date demanded a very high-depth sequencing, resulting in an elevated price of test. Herein, we developed a multimodal assay called SPOT-MAS (screening for the presence of tumor by methylation and size) to simultaneously profile methylomics, fragmentomics, copy number, and end motifs in a single workflow using targeted and shallow genome-wide sequencing (~0.55×) of cell-free DNA. We applied SPOT-MAS to 738 non-metastatic patients with breast, colorectal, gastric, lung, and liver cancer, and 1550 healthy controls. We then employed machine learning to extract multiple cancer and tissue-specific signatures for detecting and locating cancer. SPOT-MAS successfully detected the five cancer types with a sensitivity of 72.4% at 97.0% specificity. The sensitivities for detecting early-stage cancers were 73.9% and 62.3% for stages I and II, respectively, increasing to 88.3% for non-metastatic stage IIIA. For tumor-of-origin, our assay achieved an accuracy of 0.7. Our study demonstrates comparable performance to other ctDNA-based assays while requiring significantly lower sequencing depth, making it economically feasible for population-wide screening.
  • Zugangsstatus: Freier Zugang